Cytori soars after FDA permits ATHENA to move forward
This article was originally published in Scrip
Executive Summary
Shares of Cytori Therapeutics soared about 46% on 23 October after the FDA gave the all clear for the firm's ATHENA studies of its experimental adipose-derived regenerative cells (ADRCs) therapy to proceed.